{
  "query": "INSERT INTO protocols (title, diseasesite, stage, modality, intent, totalDose, fractions, dosePerFraction, targetVolume, oarConstraints, technique, clinicalNotes, references, isActive, createdBy, createdAt, updatedAt) VALUES\n('Head and Neck IMRT - Definitive Treatment', 'Head and Neck', 'Locally Advanced', 'IMRT', 'definitive', '70 Gy', 35, '2 Gy', 'PTV70 (primary tumor + involved nodes), PTV63 (high-risk subclinical disease), PTV56 (low-risk subclinical disease). Use simultaneous integrated boost (SIB) technique.', 'Spinal cord max <45 Gy, Brainstem max <54 Gy, Parotids mean <26 Gy (at least one <20 Gy), Mandible max <70 Gy, Larynx mean <45 Gy, Brachial plexus max <66 Gy, Oral cavity mean <40 Gy', '7-9 coplanar beams, avoid direct anterior/posterior beams through oral cavity. Optimize beam angles to spare parotids and spinal cord. Planning objectives: PTV70 V95% >95%, V107% <5%; PTV63/56 V95% >95%. Minimize hot spots >110%.', 'Consider adaptive replanning at fraction 15-20 due to anatomic changes (tumor regression, weight loss). Daily CBCT for setup verification. Concurrent chemotherapy standard for most patients.', 'NCCN Guidelines Head and Neck Cancers, RTOG 0522, RTOG 1016', 1, 1, NOW(), NOW()),\n\n('Prostate IMRT with Pelvic Nodes', 'Prostate', 'High Risk', 'IMRT', 'definitive', '79.2 Gy / 50.4 Gy', 44, '1.8 Gy', 'PTV prostate + seminal vesicles to 79.2 Gy, PTV pelvic lymph nodes to 50.4 Gy (28 fractions). Sequential boost technique.', 'Rectum V70 <20%, V60 <35%, V50 <50%; Bladder V70 <35%, V65 <50%; Femoral heads V50 <5%; Small bowel V45 <200cc; Penile bulb mean <52.5 Gy', '7-9 coplanar beams, avoid lateral beams through femoral heads. Anterior oblique beams to spare rectum. Prostate PTV V95% >95%, V107% <2%. Treat nodes to 50.4 Gy then cone down to prostate.', 'Full bladder and empty rectum protocol for simulation and treatment. Fiducial markers for IGRT recommended. Daily CBCT or kV imaging. Consider rectal spacer for dose reduction. Concurrent ADT for high-risk patients.', 'NCCN Prostate Cancer Guidelines, RTOG 0126, CHHiP trial', 1, 1, NOW(), NOW()),\n\n('Whole Breast IMRT with Tumor Bed Boost', 'Breast', 'Early Stage', 'IMRT', 'adjuvant', '50 Gy / 60 Gy', 25, '2 Gy', 'PTV whole breast to 50 Gy (25 fractions), PTV tumor bed boost to additional 10 Gy (5 fractions). Sequential boost technique.', 'Heart mean <4 Gy, V5 <40%; Ipsilateral lung V20 <20%, V5 <50%; Contralateral breast <3 Gy mean; Contralateral lung <2 Gy mean; Thyroid mean <20 Gy', 'Tangential field-in-field or IMRT technique with 2-4 beams. Optimize to minimize hot spots and improve dose homogeneity. Whole breast PTV V95% >95%, dose homogeneity <107%. Boost PTV V95% >95%.', 'Consider deep inspiration breath hold (DIBH) for left-sided breast cancer to reduce heart dose. Weekly port films or CBCT for setup verification. Assess for regional nodal irradiation based on pathologic features.', 'NCCN Breast Cancer Guidelines, RTOG 1005, UK START trials', 1, 1, NOW(), NOW()),\n\n('Lung SBRT - Peripheral Tumor', 'Lung', 'Early Stage', 'SBRT', 'definitive', '54 Gy', 3, '18 Gy', 'ITV (internal target volume from 4D-CT encompassing all respiratory phases), PTV = ITV + 5mm. Peripheral tumor >2cm from proximal bronchial tree.', 'Total lung V20 <10%, mean lung dose <8 Gy; Spinal cord max <18 Gy; Esophagus max <27 Gy; Heart V30 <15cc; Chest wall V30 <30cc; Brachial plexus max <24 Gy; Trachea/proximal bronchial tree max <35 Gy', '2-3 VMAT partial or full arcs. Non-coplanar beams if needed for superior tumors. PTV V100% >95%, conformity index 1.0-1.2, gradient index <5.0. Heterogeneity correction mandatory (Type B/C algorithm).', '4D-CT for motion assessment required. CBCT before each fraction. Consider gating or tracking for motion >1cm. Verify ITV adequacy with 4D-CBCT. Peripheral location critical for safety.', 'RTOG 0618, RTOG 0915, ASTRO SBRT Guidelines', 1, 1, NOW(), NOW()),\n\n('Lung SBRT - Central Tumor', 'Lung', 'Early Stage', 'SBRT', 'definitive', '50 Gy', 5, '10 Gy', 'ITV from 4D-CT, PTV = ITV + 5mm. Central tumor within 2cm of proximal bronchial tree or mediastinum.', 'Total lung V20 <10%, mean lung dose <8 Gy; Spinal cord max <26 Gy; Esophagus max <30 Gy; Heart V30 <15cc; Proximal bronchial tree max <40 Gy (point dose), V35 <4cc; Trachea max <40 Gy; Great vessels max <45 Gy', '2-3 VMAT arcs with careful optimization around central structures. PTV V100% >95%, conformity index 1.0-1.3. Accept lower conformity to respect OAR constraints.', 'RTOG 0813 established 50 Gy in 5 fractions as safe for central tumors. Daily 4D-CBCT. Consider adaptive planning if anatomy changes significantly. 2-year primary tumor control >90%.', 'RTOG 0813, RTOG 0915, HILUS trial', 1, 1, NOW(), NOW()),\n\n('Liver SBRT - Metastases', 'Liver', 'Oligometastatic', 'SBRT', 'definitive', '50 Gy', 5, '10 Gy', 'GTV = visible tumor on all imaging, ITV from 4D-CT or breath-hold scans, PTV = ITV + 5mm. Limit to 1-3 lesions, each <6cm.', 'Liver mean dose based on normal liver volume: >700cc normal liver, mean <13 Gy; 500-700cc, mean <9 Gy; <500cc, consider reduced dose or fractionation. Stomach/duodenum max <30 Gy, V25 <5cc; Small bowel max <30 Gy; Spinal cord max <26 Gy; Kidneys V15 <35%', '2-3 VMAT arcs. Non-coplanar beams may improve conformity. PTV V100% >95%, conformity index <1.3. Prioritize OAR constraints over target coverage if necessary.', '4D-CT or multiple breath-hold CTs for motion assessment. Abdominal compression or active breathing control to reduce motion. Daily CBCT with liver window. Consider fiducials for tracking. Child-Pugh A/B only.', 'RTOG 1112, NRG-BR001, SABR-COMET trial', 1, 1, NOW(), NOW()),\n\n('Spine SBRT - Metastases', 'Spine', 'Metastatic', 'SBRT', 'palliative', '24 Gy', 2, '12 Gy', 'GTV = visible tumor on MRI/CT, CTV = GTV + margin for microscopic disease (typically 2-3mm), PTV = CTV + 2mm. Epidural involvement acceptable if no cord compression.', 'Spinal cord max <14 Gy (point dose <0.035cc), V10 <10%; Cauda equina max <16 Gy; Esophagus max <18 Gy; Bowel max <20 Gy, V12.4 <5cc; Kidneys mean <8 Gy', '7-11 non-coplanar IMRT beams or 2-3 VMAT arcs. Highly conformal planning essential. CTV V100% >90%, PTV V90% >90%. Steep dose gradient at cord interface critical.', 'High-resolution MRI for target delineation mandatory. Rigid immobilization. Stereotactic localization (cone-beam CT or ExacTrac). No prior RT to same level or cord max <50 Gy equivalent. Pain relief in 80-90% of patients.', 'RTOG 0631, ASTRO SBRT Guidelines for Spine Mets', 1, 1, NOW(), NOW()),\n\n('Brain SRS - Single Metastasis', 'Brain', 'Metastatic', 'SRS', 'palliative', '20 Gy', 1, '20 Gy', 'GTV = enhancing tumor on T1 post-contrast MRI, PTV = GTV + 1-2mm (frameless) or GTV + 0mm (frame-based). Limit to lesions <3cm diameter.', 'Brainstem max <15 Gy (point dose), V12 <0.5cc; Optic chiasm max <8 Gy; Optic nerves max <8 Gy; Eyes max <8 Gy; Cochlea mean <4 Gy; Hippocampi max <9 Gy (if possible); Normal brain V12 <10cc', 'Multiple non-coplanar arcs (VMAT) or dynamic conformal arcs. 5-15 beams for LINAC-based, 192 beams for Gamma Knife. PTV V100% >95%, conformity index 1.0-1.2, gradient index <3.0.', 'Thin-slice (1mm) MRI with gadolinium for planning. Rigid immobilization (frame or frameless mask). Daily or pre-treatment imaging verification. Consider whole brain RT vs SRS based on number of lesions and prognosis. Local control 80-95% at 1 year.', 'RTOG 9005 dose escalation, RTOG 1270, ASTRO SRS Guidelines', 1, 1, NOW(), NOW()),\n\n('Brain SRS - Multiple Metastases', 'Brain', 'Metastatic', 'SRS', 'palliative', '20 Gy', 1, '20 Gy', 'GTV = enhancing tumor on T1 MRI for each lesion, PTV = GTV + 1-2mm. Treat 2-10 lesions in single session, each <3cm. Total tumor volume <15cc preferred.', 'Brainstem max <15 Gy, V12 <0.5cc; Optic apparatus max <8 Gy; Normal brain V12 <20cc (cumulative); Minimize overlap of 12 Gy isodose lines between lesions', 'Multiple non-coplanar VMAT arcs optimized for all targets simultaneously. Single isocenter technique for efficiency. PTV V100% >95% for each lesion, conformity index 1.0-1.3, minimize integral dose to normal brain.', 'Limit to good performance status patients (KPS ≥70). Consider hippocampal avoidance if possible. Frameless systems allow treatment of multiple lesions efficiently. Median survival 8-12 months. Repeat SRS for new lesions feasible.', 'JLGK0901 study, ASTRO SRS Guidelines, SRS-Quant', 1, 1, NOW(), NOW()),\n\n('Esophageal Cancer VMAT', 'Esophagus', 'Locally Advanced', 'VMAT', 'definitive', '50.4 Gy', 28, '1.8 Gy', 'GTV = primary tumor + involved nodes on PET-CT, CTV = GTV + 3-4cm superior/inferior + 1cm radial + elective nodes, PTV = CTV + 5-8mm (respiratory motion considered).', 'Spinal cord max <45 Gy; Heart mean <26 Gy, V30 <46%, V40 <100cc; Lung V20 <30%, V5 <60%, mean <18 Gy; Liver mean <30 Gy; Kidneys V20 <32%', '2-3 VMAT arcs. Avoid direct posterior beams through spinal cord. PTV V95% >95%, V107% <2%. Minimize lung dose while maintaining target coverage. Consider 4D-CT for lower third tumors.', 'PET-CT for GTV delineation improves accuracy. Concurrent chemotherapy (carboplatin/paclitaxel or FOLFOX) standard. Daily CBCT. Nutritional support critical. Elective nodal coverage per institutional guidelines (typically 2-field vs 3-field technique).', 'NCCN Esophageal Cancer Guidelines, CROSS trial, RTOG 0436', 1, 1, NOW(), NOW()),\n\n('Rectal Cancer VMAT - Neoadjuvant', 'Rectum', 'Locally Advanced', 'VMAT', 'neoadjuvant', '50.4 Gy', 28, '1.8 Gy', 'CTV = mesorectum + tumor + presacral/internal iliac nodes, PTV = CTV + 7-10mm. Consider tumor bed boost to 54-55 Gy (additional 2 fractions).', 'Small bowel V45 <200cc, V40 <300cc; Bladder V50 <50%, mean <40 Gy; Femoral heads V40 <50%; Genitalia mean <20 Gy; Bone marrow (pelvic bones) V10 <90%, V20 <75%', '2 full VMAT arcs or 3-4 partial arcs. Avoid direct anterior beams through bladder and small bowel. Mesorectal PTV V95% >95%. Minimize small bowel dose - prone position with belly board preferred.', 'Full bladder protocol to displace small bowel. Rectal contrast to delineate tumor. MRI fusion for improved GTV delineation. Concurrent capecitabine standard. Surgery 6-8 weeks after completion. Pathologic complete response in 15-20%.', 'NCCN Rectal Cancer Guidelines, German CAO/ARO/AIO-94 trial', 1, 1, NOW(), NOW()),\n\n('Pancreatic Cancer SBRT', 'Pancreas', 'Borderline Resectable', 'SBRT', 'neoadjuvant', '33 Gy', 5, '6.6 Gy', 'GTV = primary tumor on contrast CT/MRI, PTV = GTV + 3-5mm. Limit to tumors <5cm without distant metastases. Borderline resectable or locally advanced.', 'Duodenum max <33 Gy, V25 <5cc, V20 <9cc; Stomach max <33 Gy, V25 <5cc; Small bowel max <30 Gy, V25 <5cc; Liver mean <15 Gy; Kidneys V15 <35%; Spinal cord max <25 Gy', '2-3 VMAT arcs with tight conformality. PTV V100% >95%, V110% <5%. Prioritize GI OAR constraints - may accept PTV V95% >90% if necessary. Steep dose gradient essential.', '4D-CT for motion assessment. Consider fiducials for tracking. Abdominal compression or breath-hold to reduce motion. Daily CBCT. Typically after induction chemotherapy (FOLFIRINOX or Gem/Abraxane). Surgery evaluation 4-8 weeks post-RT if resectable.', 'NCCN Pancreatic Cancer Guidelines, LAPC-1 trial, Alliance A021501', 1, 1, NOW(), NOW())",
  "command": "mysql --batch --raw --column-names --default-character-set=utf8mb4 --host gateway02.us-east-1.prod.aws.tidbcloud.com --port 4000 --user 345pWMaQPV1VyKp.5c2d3a564afb --database H7NKxTnRHVSBYRhL64LnAp --execute INSERT INTO protocols (title, diseasesite, stage, modality, intent, totalDose, fractions, dosePerFraction, targetVolume, oarConstraints, technique, clinicalNotes, references, isActive, createdBy, createdAt, updatedAt) VALUES\n('Head and Neck IMRT - Definitive Treatment', 'Head and Neck', 'Locally Advanced', 'IMRT', 'definitive', '70 Gy', 35, '2 Gy', 'PTV70 (primary tumor + involved nodes), PTV63 (high-risk subclinical disease), PTV56 (low-risk subclinical disease). Use simultaneous integrated boost (SIB) technique.', 'Spinal cord max <45 Gy, Brainstem max <54 Gy, Parotids mean <26 Gy (at least one <20 Gy), Mandible max <70 Gy, Larynx mean <45 Gy, Brachial plexus max <66 Gy, Oral cavity mean <40 Gy', '7-9 coplanar beams, avoid direct anterior/posterior beams through oral cavity. Optimize beam angles to spare parotids and spinal cord. Planning objectives: PTV70 V95% >95%, V107% <5%; PTV63/56 V95% >95%. Minimize hot spots >110%.', 'Consider adaptive replanning at fraction 15-20 due to anatomic changes (tumor regression, weight loss). Daily CBCT for setup verification. Concurrent chemotherapy standard for most patients.', 'NCCN Guidelines Head and Neck Cancers, RTOG 0522, RTOG 1016', 1, 1, NOW(), NOW()),\n\n('Prostate IMRT with Pelvic Nodes', 'Prostate', 'High Risk', 'IMRT', 'definitive', '79.2 Gy / 50.4 Gy', 44, '1.8 Gy', 'PTV prostate + seminal vesicles to 79.2 Gy, PTV pelvic lymph nodes to 50.4 Gy (28 fractions). Sequential boost technique.', 'Rectum V70 <20%, V60 <35%, V50 <50%; Bladder V70 <35%, V65 <50%; Femoral heads V50 <5%; Small bowel V45 <200cc; Penile bulb mean <52.5 Gy', '7-9 coplanar beams, avoid lateral beams through femoral heads. Anterior oblique beams to spare rectum. Prostate PTV V95% >95%, V107% <2%. Treat nodes to 50.4 Gy then cone down to prostate.', 'Full bladder and empty rectum protocol for simulation and treatment. Fiducial markers for IGRT recommended. Daily CBCT or kV imaging. Consider rectal spacer for dose reduction. Concurrent ADT for high-risk patients.', 'NCCN Prostate Cancer Guidelines, RTOG 0126, CHHiP trial', 1, 1, NOW(), NOW()),\n\n('Whole Breast IMRT with Tumor Bed Boost', 'Breast', 'Early Stage', 'IMRT', 'adjuvant', '50 Gy / 60 Gy', 25, '2 Gy', 'PTV whole breast to 50 Gy (25 fractions), PTV tumor bed boost to additional 10 Gy (5 fractions). Sequential boost technique.', 'Heart mean <4 Gy, V5 <40%; Ipsilateral lung V20 <20%, V5 <50%; Contralateral breast <3 Gy mean; Contralateral lung <2 Gy mean; Thyroid mean <20 Gy', 'Tangential field-in-field or IMRT technique with 2-4 beams. Optimize to minimize hot spots and improve dose homogeneity. Whole breast PTV V95% >95%, dose homogeneity <107%. Boost PTV V95% >95%.', 'Consider deep inspiration breath hold (DIBH) for left-sided breast cancer to reduce heart dose. Weekly port films or CBCT for setup verification. Assess for regional nodal irradiation based on pathologic features.', 'NCCN Breast Cancer Guidelines, RTOG 1005, UK START trials', 1, 1, NOW(), NOW()),\n\n('Lung SBRT - Peripheral Tumor', 'Lung', 'Early Stage', 'SBRT', 'definitive', '54 Gy', 3, '18 Gy', 'ITV (internal target volume from 4D-CT encompassing all respiratory phases), PTV = ITV + 5mm. Peripheral tumor >2cm from proximal bronchial tree.', 'Total lung V20 <10%, mean lung dose <8 Gy; Spinal cord max <18 Gy; Esophagus max <27 Gy; Heart V30 <15cc; Chest wall V30 <30cc; Brachial plexus max <24 Gy; Trachea/proximal bronchial tree max <35 Gy', '2-3 VMAT partial or full arcs. Non-coplanar beams if needed for superior tumors. PTV V100% >95%, conformity index 1.0-1.2, gradient index <5.0. Heterogeneity correction mandatory (Type B/C algorithm).', '4D-CT for motion assessment required. CBCT before each fraction. Consider gating or tracking for motion >1cm. Verify ITV adequacy with 4D-CBCT. Peripheral location critical for safety.', 'RTOG 0618, RTOG 0915, ASTRO SBRT Guidelines', 1, 1, NOW(), NOW()),\n\n('Lung SBRT - Central Tumor', 'Lung', 'Early Stage', 'SBRT', 'definitive', '50 Gy', 5, '10 Gy', 'ITV from 4D-CT, PTV = ITV + 5mm. Central tumor within 2cm of proximal bronchial tree or mediastinum.', 'Total lung V20 <10%, mean lung dose <8 Gy; Spinal cord max <26 Gy; Esophagus max <30 Gy; Heart V30 <15cc; Proximal bronchial tree max <40 Gy (point dose), V35 <4cc; Trachea max <40 Gy; Great vessels max <45 Gy', '2-3 VMAT arcs with careful optimization around central structures. PTV V100% >95%, conformity index 1.0-1.3. Accept lower conformity to respect OAR constraints.', 'RTOG 0813 established 50 Gy in 5 fractions as safe for central tumors. Daily 4D-CBCT. Consider adaptive planning if anatomy changes significantly. 2-year primary tumor control >90%.', 'RTOG 0813, RTOG 0915, HILUS trial', 1, 1, NOW(), NOW()),\n\n('Liver SBRT - Metastases', 'Liver', 'Oligometastatic', 'SBRT', 'definitive', '50 Gy', 5, '10 Gy', 'GTV = visible tumor on all imaging, ITV from 4D-CT or breath-hold scans, PTV = ITV + 5mm. Limit to 1-3 lesions, each <6cm.', 'Liver mean dose based on normal liver volume: >700cc normal liver, mean <13 Gy; 500-700cc, mean <9 Gy; <500cc, consider reduced dose or fractionation. Stomach/duodenum max <30 Gy, V25 <5cc; Small bowel max <30 Gy; Spinal cord max <26 Gy; Kidneys V15 <35%', '2-3 VMAT arcs. Non-coplanar beams may improve conformity. PTV V100% >95%, conformity index <1.3. Prioritize OAR constraints over target coverage if necessary.', '4D-CT or multiple breath-hold CTs for motion assessment. Abdominal compression or active breathing control to reduce motion. Daily CBCT with liver window. Consider fiducials for tracking. Child-Pugh A/B only.', 'RTOG 1112, NRG-BR001, SABR-COMET trial', 1, 1, NOW(), NOW()),\n\n('Spine SBRT - Metastases', 'Spine', 'Metastatic', 'SBRT', 'palliative', '24 Gy', 2, '12 Gy', 'GTV = visible tumor on MRI/CT, CTV = GTV + margin for microscopic disease (typically 2-3mm), PTV = CTV + 2mm. Epidural involvement acceptable if no cord compression.', 'Spinal cord max <14 Gy (point dose <0.035cc), V10 <10%; Cauda equina max <16 Gy; Esophagus max <18 Gy; Bowel max <20 Gy, V12.4 <5cc; Kidneys mean <8 Gy', '7-11 non-coplanar IMRT beams or 2-3 VMAT arcs. Highly conformal planning essential. CTV V100% >90%, PTV V90% >90%. Steep dose gradient at cord interface critical.', 'High-resolution MRI for target delineation mandatory. Rigid immobilization. Stereotactic localization (cone-beam CT or ExacTrac). No prior RT to same level or cord max <50 Gy equivalent. Pain relief in 80-90% of patients.', 'RTOG 0631, ASTRO SBRT Guidelines for Spine Mets', 1, 1, NOW(), NOW()),\n\n('Brain SRS - Single Metastasis', 'Brain', 'Metastatic', 'SRS', 'palliative', '20 Gy', 1, '20 Gy', 'GTV = enhancing tumor on T1 post-contrast MRI, PTV = GTV + 1-2mm (frameless) or GTV + 0mm (frame-based). Limit to lesions <3cm diameter.', 'Brainstem max <15 Gy (point dose), V12 <0.5cc; Optic chiasm max <8 Gy; Optic nerves max <8 Gy; Eyes max <8 Gy; Cochlea mean <4 Gy; Hippocampi max <9 Gy (if possible); Normal brain V12 <10cc', 'Multiple non-coplanar arcs (VMAT) or dynamic conformal arcs. 5-15 beams for LINAC-based, 192 beams for Gamma Knife. PTV V100% >95%, conformity index 1.0-1.2, gradient index <3.0.', 'Thin-slice (1mm) MRI with gadolinium for planning. Rigid immobilization (frame or frameless mask). Daily or pre-treatment imaging verification. Consider whole brain RT vs SRS based on number of lesions and prognosis. Local control 80-95% at 1 year.', 'RTOG 9005 dose escalation, RTOG 1270, ASTRO SRS Guidelines', 1, 1, NOW(), NOW()),\n\n('Brain SRS - Multiple Metastases', 'Brain', 'Metastatic', 'SRS', 'palliative', '20 Gy', 1, '20 Gy', 'GTV = enhancing tumor on T1 MRI for each lesion, PTV = GTV + 1-2mm. Treat 2-10 lesions in single session, each <3cm. Total tumor volume <15cc preferred.', 'Brainstem max <15 Gy, V12 <0.5cc; Optic apparatus max <8 Gy; Normal brain V12 <20cc (cumulative); Minimize overlap of 12 Gy isodose lines between lesions', 'Multiple non-coplanar VMAT arcs optimized for all targets simultaneously. Single isocenter technique for efficiency. PTV V100% >95% for each lesion, conformity index 1.0-1.3, minimize integral dose to normal brain.', 'Limit to good performance status patients (KPS ≥70). Consider hippocampal avoidance if possible. Frameless systems allow treatment of multiple lesions efficiently. Median survival 8-12 months. Repeat SRS for new lesions feasible.', 'JLGK0901 study, ASTRO SRS Guidelines, SRS-Quant', 1, 1, NOW(), NOW()),\n\n('Esophageal Cancer VMAT', 'Esophagus', 'Locally Advanced', 'VMAT', 'definitive', '50.4 Gy', 28, '1.8 Gy', 'GTV = primary tumor + involved nodes on PET-CT, CTV = GTV + 3-4cm superior/inferior + 1cm radial + elective nodes, PTV = CTV + 5-8mm (respiratory motion considered).', 'Spinal cord max <45 Gy; Heart mean <26 Gy, V30 <46%, V40 <100cc; Lung V20 <30%, V5 <60%, mean <18 Gy; Liver mean <30 Gy; Kidneys V20 <32%', '2-3 VMAT arcs. Avoid direct posterior beams through spinal cord. PTV V95% >95%, V107% <2%. Minimize lung dose while maintaining target coverage. Consider 4D-CT for lower third tumors.', 'PET-CT for GTV delineation improves accuracy. Concurrent chemotherapy (carboplatin/paclitaxel or FOLFOX) standard. Daily CBCT. Nutritional support critical. Elective nodal coverage per institutional guidelines (typically 2-field vs 3-field technique).', 'NCCN Esophageal Cancer Guidelines, CROSS trial, RTOG 0436', 1, 1, NOW(), NOW()),\n\n('Rectal Cancer VMAT - Neoadjuvant', 'Rectum', 'Locally Advanced', 'VMAT', 'neoadjuvant', '50.4 Gy', 28, '1.8 Gy', 'CTV = mesorectum + tumor + presacral/internal iliac nodes, PTV = CTV + 7-10mm. Consider tumor bed boost to 54-55 Gy (additional 2 fractions).', 'Small bowel V45 <200cc, V40 <300cc; Bladder V50 <50%, mean <40 Gy; Femoral heads V40 <50%; Genitalia mean <20 Gy; Bone marrow (pelvic bones) V10 <90%, V20 <75%', '2 full VMAT arcs or 3-4 partial arcs. Avoid direct anterior beams through bladder and small bowel. Mesorectal PTV V95% >95%. Minimize small bowel dose - prone position with belly board preferred.', 'Full bladder protocol to displace small bowel. Rectal contrast to delineate tumor. MRI fusion for improved GTV delineation. Concurrent capecitabine standard. Surgery 6-8 weeks after completion. Pathologic complete response in 15-20%.', 'NCCN Rectal Cancer Guidelines, German CAO/ARO/AIO-94 trial', 1, 1, NOW(), NOW()),\n\n('Pancreatic Cancer SBRT', 'Pancreas', 'Borderline Resectable', 'SBRT', 'neoadjuvant', '33 Gy', 5, '6.6 Gy', 'GTV = primary tumor on contrast CT/MRI, PTV = GTV + 3-5mm. Limit to tumors <5cm without distant metastases. Borderline resectable or locally advanced.', 'Duodenum max <33 Gy, V25 <5cc, V20 <9cc; Stomach max <33 Gy, V25 <5cc; Small bowel max <30 Gy, V25 <5cc; Liver mean <15 Gy; Kidneys V15 <35%; Spinal cord max <25 Gy', '2-3 VMAT arcs with tight conformality. PTV V100% >95%, V110% <5%. Prioritize GI OAR constraints - may accept PTV V95% >90% if necessary. Steep dose gradient essential.', '4D-CT for motion assessment. Consider fiducials for tracking. Abdominal compression or breath-hold to reduce motion. Daily CBCT. Typically after induction chemotherapy (FOLFIRINOX or Gem/Abraxane). Surgery evaluation 4-8 weeks post-RT if resectable.', 'NCCN Pancreatic Cancer Guidelines, LAPC-1 trial, Alliance A021501', 1, 1, NOW(), NOW())",
  "returncode": 1,
  "logs": [
    "ERROR 1064 (42000) at line 1: You have an error in your SQL syntax; check the manual that corresponds to your TiDB version for the right syntax to use line 1 column 173 near \"references, isActive, createdBy, createdAt, updatedAt) VALUES",
    "('Head and Neck IMRT - Definitive Treatment', 'Head and Neck', 'Locally Advanced', 'IMRT', 'definitive', '70 Gy', 35, '2 Gy', 'PTV70 (primary tumor + involved nodes), PTV63 (high-risk subclinical disease), PTV56 (low-risk subclinical disease). Use simultaneous integrated boost (SIB) technique.', 'Spinal"
  ]
}